CARDIOVASCULAR INVOLVEMENT IN BRONCHOPULMONARY DYSPLASIA
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Introduction and Objective: While neonatal intensive care has improved survival for extremely preterm infants, Bronchopulmonary Dysplasia (BPD) persists as their most common chronic illness. We now understand BPD not simply as a lung disease, but as a multisystem disorder where cardiovascular complications, particularly Pulmonary Hypertension (PH), drive its significant morbidity and mortality. This summary outlines the cardiac consequences of BPD and reviews current strategies for clinical management.Pathophysiology and Findings: At its core, the modern “New BPD” is characterized by a halt in distal lung growth, combined with severely disordered development of the pulmonary blood vessels. This process, known as Pulmonary Vascular Dysplasia (PVD), causes persistently high pulmonary vascular resistance (PVR). The resulting PH, which develops in roughly 20-25% of infants with BPD, is the primary driver of mortality. The relentless pressure overload forces the right ventricle (RV) first to thicken (hypertrophy) and then ultimately fail. Concurrently, these infants often develop left ventricular diastolic dysfunction (LVDD) and face a greater risk of systemic hypertension.Risks and Management: Treatment itself presents a significant challenge. The use of postnatal systemic corticosteroids (PNS) introduces severe, dose-dependent risks. For instance, while late-administered dexamethasone can reduce BPD, it also substantially increases the risk for both hypertension (RR 2.12) and hypertrophic cardiomyopathy (HOCM) (RR 2.76). Early detection through tools like transthoracic echocardiography (TTE) and biomarkers such as BNP and NT-proBNP is crucial for monitoring ventricular strain. Managing these complex cases requires a coordinated, multidisciplinary team utilizing PH-targeted pulmonary vasodilators.Conclusion: PH is the central driver of poor outcomes in BPD. Because survivors carry a lifelong burden of reduced cardiac reserve and an elevated risk for congestive heart failure, improving their long-term health depends critically on the judicious use of steroids and vigilant, early detection of pulmonary hypertension.Keywords: Bronchopulmonary dysplasia; Cardiovascular system
Fields of Study & Subjects
Neonatal Respiratory Health Research
Pulmonary Hypertension Research and Treatments
Cardiovascular Conditions and Treatments
Publication details
- Journal / source
- Turkiye Klinikleri eBooks
- Pages
- 429–436
- Publication date
- 1 January 2026
- Language
- EN
- Document type
- Book chapter